Biliary atresia is a condition in infants in which the bile ducts—tubes inside and outside the liver—are scarred and blocked. Bile ducts carry bile from the liver to the gallbladder for storage, and to the first part of the small intestine, also called the duodenum, for use in digestion. In infants with biliary atresia, bile can’t flow into the intestine, so bile builds up in the liver and damages it. The damage leads to scarring, loss of liver tissue and function, and cirrhosis.
There are two types of biliary atresia, a fetal form, which develops during fetal life and is present at birth, and a more common perinatal form, which does not become evident until the second to fourth week of the infant's life. Some children, particularly those with the fetal form of biliary atresia, have other birth defects in the heart, spleen, or intestines. Biliary atresia is life-threatening, but with treatment, most infants with biliary atresia survive to adulthood.
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Biliary Atresia market report also covers emerging drugs, current treatment practices, Biliary Atresia market size and share of the individual therapies, current and forecasted Biliary Atresia Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Biliary Atresia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Biliary Atresia Market Key Facts
-
According to the National Organization for Rare Disorders, Biliary Atresia occurs in approximately 1 in 10,000 to 15,000 births in the United States.
-
Approximately 400-600 new cases of biliary atresia are encountered in the United States each year.
-
According to one estimate, the prevalence of biliary atresia in Europe is approximately 1 in 12,000 births.
Biliary Atresia Market Analysis
The Biliary Atresia market size is anticipated to increase during the study period, 2017–2030. The key driver for the surge in market size is the rise in the number of incident cases of Biliary Atresia patients in 7MM.
The Biliary Atresia market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Biliary Atresia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
The report gives a thorough detail of Biliary Atresia market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Biliary Atresia Epidemiology Forecast
The Biliary Atresia epidemiology section covers insights about historical and current Biliary Atresia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Biliary Atresia Pipeline Analysis and Key Market Players
The Biliary Atresia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched in the market during the study period. The analysis covers Biliary Atresia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Biliary Atresia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecast period.
Some of the key players involved in developing therapies for Biliary Atresia includes Sirnaomics and Albireo.
For more detailed information on Biliary Atresia Market, visit: https://www.delveinsight.com/report-store/biliary-atresia-market